Adam Dubow - 15 Nov 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
General Counsel
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
15 Nov 2023
Net transactions value
-$62,109
Form type
4
Filing time
17 Nov 2023, 18:30:24 UTC
Previous filing
16 Nov 2023
Next filing
09 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +11,850 +377% 14,991 15 Nov 2023 Direct F1
transaction DAWN Common Stock Options Exercise +1,750 +12% 16,741 15 Nov 2023 Direct F1
transaction DAWN Common Stock Sale $62,109 -5,313 -32% $11.69 11,428 16 Nov 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -11,850 -25% $0.000000 35,550 15 Nov 2023 Common Stock 11,850 Direct F1, F3
transaction DAWN Restricted Stock Units Options Exercise $0 -1,750 -7.7% $0.000000 21,000 15 Nov 2023 Common Stock 1,750 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.